With an aging population, the focus on controlling costs and improving quality in long term care becomes paramount, with increasing evidence and data pointing to the benefits of personalized medicine.Medicare compliance requirements are driving comprehensive person-centered care plans including measurable objectives for resident’s medical, nursing, mental and psychosocial needs. Facilities that embrace this value-based care will have a distinct competitive advantage as they show improved patient outcomes.
Long-term care facilities provide an ideal environment for facilitating the spread of infection, and antibiotic resistance has become a public health crisis.Respiratory and gastrointestinal infections can spread quickly among residents, particularly the immunocompromised and those with comorbidities. Delayed diagnosis and treatment for UTIs and acute and chronic wounds can lead to increased morbidity, mortality and healthcare costs. Unfortunately, there are patients every day who contract infections that cannot be treated with currently available antibiotics. Each year in the US, at least 2 million people acquire infections with bacteria resistant to one-or-more of the antibiotics designed to treat them, and at least 23,000 people die as a direct result. The medical cost per patient with an antibiotic-resistant infection is estimated to range from $18-30k.
Polypharmacy and adverse drug events are the 4th leading cause of death.In addition, they annually lead to more than 20% of hospital re-admissions and billions of dollars in extra medical costs. The number of concomitant medications and the burden of medication side effects has become so concerning that Beers criteria were developed to draw attention to high-risk medications in the elderly population.
Precision medicine solutions from Attis Healthcare enable providers to personalize care in long term care facilities and in the home health environment.PCR Molecular Pathogen ID
Conventional culture testing can take several days to weeks to result and is limited to the detection of single pathogens, often impeding the effective identification and treatment of infection. For home healthcare providers, proximity to the lab and maintaining the integrity of specimens throughout the day can prove challenging and inefficient. Advanced Real Time-PCR technology allows for the most rapid pathogen identification, quantification and detection of antibiotic resistance. Collected via non-invasive swab, PCR detects multiple pathogens at once, results in 12-24 hours and is 3-5x more sensitive than standard culture. Samples maintain their integrity regardless of time or temperature, and are shipped in a prepaid envelope via major shipping carrier drop boxes, eliminating the need to locate a lab quickly. In addition, PCR testing identifies the pathogen load and genetic variations that allow pathogens to become resistant to antibiotic. This is instrumental when selecting an effective antibiotic regimen for the patient and reducing unnecessary antibiotic use. PCR Molecular Pathogen identification is available for the detection of respiratory, urinary tract, gastrointestinal and wound infections. Pharmacogenetics (PGx) and Medication Therapy Management
Pharmacogenetics is testing for genetic differences which can affect individual responses to drugs, in terms of both therapeutic and adverse effects. By personalizing a patient’s care plan using these unique genetic characteristics, PGx and Medication Therapy Management can lead to reduced trial-and-error prescriptions, decreased time to symptom relief, significant drug and healthcare savings and improved quality of life. The PGx test is a simple cheek swab that is run once and can be used for life. A genetic response report is then generated combining genetic markers, molecular data and clinical evidence. This is where Attis’ solution takes it a step further. While PGx results once could be hard to digest and interpret, we offer an interactive medication management tool allowing the healthcare provider to “play” with alternative drug options to assess how the new therapy would affect drug-gene and drug-drug interactions, and find the scenario that presents the least amount of risk. Powered by genomic data from the Coriell Institute of Medical Research, this tool factors in genetics, demographics and lifestyle factors to help the healthcare provider make scientifically-based treatment decisions.